Zobrazeno 1 - 7
of 7
pro vyhledávání: '"S. Leigh Verbois"'
Autor:
Robert J. Parker, R. Daniel Mellon, S. Leigh Verbois, Donna A. Volpe, Aspandiar G. Katki, Thomas Colatsky, Timothy J. Kropp, Grainne A. McMahon Tobin
Publikováno v:
Regulatory Toxicology and Pharmacology. 59:385-390
The safe disposal of unused opioid drugs is an area of regulatory concern. While toilet flushing is recommended for some drugs to prevent accidental exposure, there is a need for data that can support a more consistent disposal policy based on an ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::414911e739da6b7f09e204aee9fbc435
https://doi.org/10.1016/j.yrtph.2010.12.007
https://doi.org/10.1016/j.yrtph.2010.12.007
Autor:
Robert Justice, Shakun M. Malik, Richard Pazdur, Rajeshwari Sridhara, Alice Kacuba, Julie Bullock, Terrance Ocheltree, Ke Liu, Gene M. Williams, Milinda Vialpando, Anshu Marathe, Shenghui Tang, S. Leigh Verbois, W. David McGuinn, Xu Qiang, Sue Ching Lin, Christoffer W. Tornøe
Publikováno v:
Clinical Cancer Research. 16:4921-4927
Purpose: On September 24, 2009, the U.S. Food and Drug Administration granted accelerated approval for Folotyn (pralatrexate injection, Allos Therapeutics, Inc.) as a single agent for the treatment of patients with relapsed or refractory peripheral T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::698d72f2a66292c526feab5d66a498e0
https://doi.org/10.1158/1078-0432.ccr-10-1214
https://doi.org/10.1158/1078-0432.ccr-10-1214
Autor:
Timothy Kropp, S. Leigh Verbois, W. David McGuinn, Hans Rosenfeldt, M. Stacey Ricci, Kimberly Benson
Publikováno v:
Toxicology and Applied Pharmacology. 243:125-133
The drug development of new anti-cancer agents is streamlined in response to the urgency of bringing effective drugs to market for patients with limited life expectancy. FDA's regulation of oncology drugs has evolved from the practices set forth in A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ff219169ffb3e51d44b405aaf3c0c49
https://doi.org/10.1016/j.taap.2009.12.020
https://doi.org/10.1016/j.taap.2009.12.020
Autor:
Jogarao V. S. Gobburu, Edwin P. Rock, Cheng Yi Liang, Sophia Abraham, Nallaperumal Chidambaram, S. Leigh Verbois, David E. Morse, Janet X. Jiang, Shenghui Tang, Richard Pazdur, Robert Justice, Roshni Ramchandani, Vicki L. Goodman, Ramzi Dagher, Brian Booth, Kooros Mahjoob
Publikováno v:
Clinical Cancer Research. 13:1367-1373
Purpose: To describe the Food and Drug Administration (FDA) review and approval of sunitinib malate (Sutent). Sunitinib received regular approval for the treatment of gastrointestinal stromal tumor (GIST) after disease progression or intolerance to i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3182d3fb195191d614a250fba0132840
https://doi.org/10.1158/1078-0432.ccr-06-2328
https://doi.org/10.1158/1078-0432.ccr-06-2328
Autor:
Sophia Abraham, Robert C. Kane, Lilliam A. Rosario, Grant R. Williams, Kimberly Benson, David E. Morse, Yong-Cheng Wang, Richard Pazdur, Sean Bradley, Cheng Yi Liang, Atiqur Rahman, Anwar Goheer, Shwu-Luan Lee, John K. Leighton, Richard T. Lostritto, Jogarao V. S. Gobburu, S. Leigh Verbois, Ann T. Farrell, William D. McGuinn, Peter F. Bross, Margaret E. Brower
Publikováno v:
Clinical Cancer Research. 10:3954-3964
Purpose: Multiple myeloma is a malignant plasma cell disorder accounting for about 10% of hematological malignancies. Despite treatment advances, including hematopoietic stem-cell transplantation to facilitate administration of high-dose cytotoxic ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f57c236ba396517258c8935d9643f5d5
https://doi.org/10.1158/1078-0432.ccr-03-0781
https://doi.org/10.1158/1078-0432.ccr-03-0781
Autor:
S. Leigh Verbois, Kooros Mahjoob, David L. Morse, Janet X. Jiang, Vicki L. Goodman, Ramzi Dagher, Richard Pazdur, Robert Justice, Edwin P. Rock
Publikováno v:
The oncologist. 12(1)
On January 26, 2006, sunitinib (Sutent) received regular approval as monotherapy for the treatment of patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate (Gleevec). Time-to-tumor progression (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d106b6d9caad339161b5830387ddefee
https://pubmed.ncbi.nlm.nih.gov/17227905
https://pubmed.ncbi.nlm.nih.gov/17227905
Publikováno v:
Journal of neurotrauma. 19(12)
Alterations in neurotransmitter receptor expression in the central nervous system may contribute to physiological and behavioral deficits that follow traumatic brain injury (TBI). Previous studies from our laboratory have demonstrated significant and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f35b98dd2dc51df66f26273974612b32
https://pubmed.ncbi.nlm.nih.gov/12542858
https://pubmed.ncbi.nlm.nih.gov/12542858